Data supported our hypothesis and demonstrated that 4 days following STZ administration, 35 mg/kg-treated mice secreted significantly more insulin than 55 mg/kg-treated mice and, therefore, were able to better manage hyperglycemia despite having similar levels of beta cell mass loss. The gene discussed is INS; the disease is Hyperglycemia.